Venus Remedies Presents GMP Certification by Libya

Venus Remedies has been awarded a Good Manufacturing Practice (GMP) certificate for its facilities by the Libyan Ministry of Health. Libya's pharmaceutical imports, estimated at $514 million in 2021, increased by 2.81 percent compared to the previous year.

Its strategic location in Africa and evolving pharmaceutical landscape provide Venus Remedies with an opportunity to contribute positively to the region's healthcare sector. The $46.8 billion pharmaceutical market of Africa, as of 2022, is expected to grow at a CAGR of 8.3 per cent to reach $110.9 billion by 2023. This certification is a step towards enhancing the company's presence in Africa, as per pharmabiz.

Saransh Chaudhary, CEO, Venus Medicine Research Centre, said, “The GMP certification from Libya adds to Venus Remedies' portfolio of international approvals from 25 regulators, complementing our existing certifications in Africa from Morocco, South Africa, Tanzania, Kenya, Uganda, Sudan, and other African countries. This GMP certification reflects our collaborative efforts in the African pharmaceutical industry, a key focus area of our global expansion strategy.”

Akshansh Chaudhary, Executive Director, Venus Remedies, said, “We are thankful to our customers, partners, and stakeholders for their constant support. Their trust in our company drives our pursuit of excellence.”

Venus is a fully integrated company known worldwide for its research and development initiatives and breakthroughs in the field of antimicrobial resistance. The consequences of antibiotic resistance and the causes and treatment of antibiotic-resistant bacteria are highlighted through extensive research and the synergistic work of a team of experienced scientists and specialists at the state-of-the-art research facility at the Venus Medicine Research Center (VMRC).